Literature DB >> 24363153

The evaluation method for antiplatelet effect of acetylsalicylic acid.

Haruko Yokoyama1, Takashi Mastumura, Shinji Soeda, Yuji Suzuki, Masayuki Watanabe, Emiko Kashiwakura, Takayuki Saso, Noriyuki Ikeda, Kentaro Tokuoka, Yasuhisa Kitagawa, Yasuhiko Yamada.   

Abstract

Reduced platelet aggregation by acetylsalicylic acid administration has been associated with adverse outcomes in patients with thrombotic diseases, thus it is important to determine aspirin resistance in those cases. The antiplatelet effect of acetylsalicylic acid is rarely measured, but it has many problems. The aim of this study was to find the evaluation method for antiplatelet effect after administration of acetylsalicylic acid. We developed a particle counting method based upon laser light scattering, and utilized the platelet aggregation agonists, collagen, at 0.25, 0.5 and 1.0 μg/mL, and adenosine diphosphate (ADP), at 0.5, 1.0 and 2.0 μM, to determine their effective concentrations. Seventeen healthy volunteers were administered acetylsalicylic acid at 162 mg/day, with platelet aggregation determined before and 20 min after administration. In all subjects, the rate of platelet aggregation induced by 1.0 μg/mL of collagen before taking acetylsalicylic acid was the highest value obtained, while 20 min after acetylsalicylic acid administration, aggregation induced by collagen at 1.0 μg/mL was significantly decreased as compared to before administration. As for the other concentrations of collagen and all those of ADP tested, platelet aggregation was either not significantly induced before taking acetylsalicylic acid or the rate of aggregation was not significantly decreased after taking acetylsalicylic acid. Our results indicate that collagen at 1.0 μg/mL is appropriate as a platelet aggregation agonist for evaluating the antiplatelet effect of acetylsalicylic acid. Thus, it is useful that the measurement is performed only once.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24363153     DOI: 10.1007/s13318-013-0170-9

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  16 in total

Review 1.  Aspirin.

Authors:  E H Awtry; J Loscalzo
Journal:  Circulation       Date:  2000-03-14       Impact factor: 29.690

2.  Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation.

Authors:  R L Lorenz; C V Schacky; M Weber; W Meister; J Kotzur; B Reichardt; K Theisen; P C Weber
Journal:  Lancet       Date:  1984-06-09       Impact factor: 79.321

3.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1.

Authors:  D Picot; P J Loll; R M Garavito
Journal:  Nature       Date:  1994-01-20       Impact factor: 49.962

4.  Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians.

Authors:  P M Ridker; J E Manson; J E Buring; J E Muller; C H Hennekens
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

5.  Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers.

Authors:  I H Benedek; A S Joshi; H J Pieniaszek; S Y King; D M Kornhauser
Journal:  J Clin Pharmacol       Date:  1995-12       Impact factor: 3.126

6.  Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.

Authors:  T Ohmori; Y Yatomi; T Nonaka; Y Kobayashi; S Madoiwa; J Mimuro; Y Ozaki; Y Sakata
Journal:  J Thromb Haemost       Date:  2006-06       Impact factor: 5.824

7.  Development of aspirin resistance in persons with previous ischemic stroke.

Authors:  C M Helgason; K M Bolin; J A Hoff; S R Winkler; A Mangat; K L Tortorice; L D Brace
Journal:  Stroke       Date:  1994-12       Impact factor: 7.914

8.  Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing.

Authors:  T Komiya; M Kudo; T Urabe; Y Mizuno
Journal:  Stroke       Date:  1994-12       Impact factor: 7.914

9.  Aspirin non-responder status in patients with recurrent cerebral ischemic attacks.

Authors:  K Grundmann; K Jaschonek; B Kleine; J Dichgans; H Topka
Journal:  J Neurol       Date:  2003-01       Impact factor: 4.849

10.  Clinical use of aspirin in treatment and prevention of cardiovascular disease.

Authors:  Yuxiang Dai; Junbo Ge
Journal:  Thrombosis       Date:  2011-11-24
View more
  1 in total

Review 1.  The pharmacological treatment of acute vestibular syndrome.

Authors:  Pasquale Viola; Federico Maria Gioacchini; Alessia Astorina; Davide Pisani; Alfonso Scarpa; Gianmarco Marcianò; Alessandro Casarella; Emanuele Basile; Vincenzo Rania; Massimo Re; Giuseppe Chiarella
Journal:  Front Neurol       Date:  2022-09-09       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.